12 results on '"Sasajima, T."'
Search Results
2. High accumulation of plasminogen and tissue plasminogen activator at the flow surface of mural fibrin in the human arterial system
- Author
-
Sasajima, T
- Published
- 2000
- Full Text
- View/download PDF
3. Development of gene therapy with a cyclic adenosine monophosphate response element decoy oligodeoxynucleotide to prevent vascular intimal hyperplasia.
- Author
-
Uchida D, Saito Y, Kikuchi S, Yoshida Y, Hirata S, Sasajima T, and Azuma N
- Subjects
- Animals, CREB-Binding Protein genetics, CREB-Binding Protein metabolism, Cell Movement, Cell Proliferation, Cells, Cultured, Disease Models, Animal, Humans, Intracellular Signaling Peptides and Proteins genetics, Intracellular Signaling Peptides and Proteins metabolism, LIM Domain Proteins genetics, LIM Domain Proteins metabolism, Male, Mice, Inbred C57BL, Muscle, Smooth, Vascular injuries, Muscle, Smooth, Vascular pathology, Myocytes, Smooth Muscle pathology, Oligodeoxyribonucleotides metabolism, Protein Serine-Threonine Kinases genetics, Protein Serine-Threonine Kinases metabolism, Transcription Factors genetics, Transcription Factors metabolism, Vascular System Injuries genetics, Vascular System Injuries metabolism, Vascular System Injuries pathology, Cyclic AMP metabolism, Muscle, Smooth, Vascular metabolism, Myocytes, Smooth Muscle metabolism, Neointima, Oligodeoxyribonucleotides genetics, Response Elements genetics, Vascular System Injuries prevention & control
- Abstract
Objective: Intimal hyperplasia (IH) is the main cause of therapeutic failure after vascular and endovascular surgery. However, there is currently no targeted therapy for the treatment of IH. We recently reported that the inhibition of cyclic adenosine monophosphate response element (CRE) binding protein (CREB) activation is important in vein graft IH. We focused on a decoy oligodeoxynucleotide (ODN) therapeutic strategy for suppressing IH as a clinical application. The objective of this study was to confirm the therapeutic effect of a CRE decoy ODN in an animal model as a novel therapy for preventing intimal hyperplasia as the first step of the preclinical study of our strategy., Methods: We designed two phosphorothioate CREs and two scramble decoy ODNs and screened them using a CREB transcription assay to check their ability to bind to a CRE sequence. We chose a CRE decoy ODN with high first-binding ability and transfected it into vascular smooth muscle cells (VSMCs) in vitro. Proliferation and migration were assessed using MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assays and modified Boyden chamber assays. We examined CRE activity using a luciferase reporter gene assay. We assessed the expression of messenger RNAs by quantitative real-time polymerase chain reaction. In a wire-injury mouse model (C57BL6, n = 6), CRE decoy ODN was transfected into the injured vessel wall using an ultrasound-sonoporation method in vivo. Mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3) and four and a half LIM domains 5 (FHL5) expression of pregrafting vein remnants were assessed by immunohistologic analyses., Results: Compared with scramble decoy ODN, the selected CRE decoy ODN could significantly decrease CRE activity (mean ± standard error of the mean: 0.20 ± 0.03 vs 1.00 ± 0.16, n = 6; P < .05) as shown by a luciferase reporter gene assay, VSMC proliferation (0.73 ± 0.04 vs 0.89 ± 0.02, n = 6; P < .05) and migration (96.4 ± 6.1 vs 311.4 ± 19.1 migrated VSMCs/well, n = 6; P < .05) after 24-hour transfection. The CRE decoy ODN significantly suppressed the formation of IH at injured vessel walls in an animal model, as analyzed by pathologic staining (0.20 ± 0.02 vs 0.56 ± 0.08, area of the intima/area of the artery vs the control after 21 days' transfection, n = 6; P < .05). Furthermore, MAPKAPK3 and FHL5, which are CREB activators, were significantly expressed in pregrafting vein remnants in diabetes mellitus patients., Conclusions: CREB-CRE signaling is an important mechanism of IH formation, and CRE decoy therapy can help preventing IH. This study is the first part of the preclinical study of our strategy., (Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
4. Evaluation of paramalleolar and inframalleolar bypasses in dialysis- and nondialysis-dependent patients with critical limb ischemia.
- Author
-
Kikuchi S, Sasajima T, Inaba M, Uchida D, Kokubo T, Saito Y, Koya A, Uchida H, and Azuma N
- Subjects
- Age Factors, Aged, Aged, 80 and over, Amputation, Surgical, Arteriosclerosis Obliterans diagnosis, Arteriosclerosis Obliterans mortality, Arteriosclerosis Obliterans physiopathology, Comorbidity, Critical Illness, Disease-Free Survival, Female, Humans, Ischemia diagnosis, Ischemia mortality, Ischemia physiopathology, Kaplan-Meier Estimate, Kidney physiopathology, Limb Salvage, Male, Middle Aged, Proportional Hazards Models, Renal Insufficiency, Chronic diagnosis, Renal Insufficiency, Chronic mortality, Renal Insufficiency, Chronic physiopathology, Retrospective Studies, Risk Factors, Saphenous Vein physiopathology, Sex Factors, Time Factors, Treatment Outcome, Vascular Grafting adverse effects, Vascular Grafting mortality, Vascular Patency, Arm blood supply, Arteriosclerosis Obliterans surgery, Ischemia surgery, Renal Dialysis adverse effects, Renal Dialysis mortality, Renal Insufficiency, Chronic surgery, Saphenous Vein transplantation, Vascular Grafting methods
- Abstract
Objective: The aim of this study was to elucidate the efficacy of paramalleolar or inframalleolar bypass (PIMB) in hemodialysis-dependent (HD) patients with critical limb ischemia (CLI) and nonhemodialysis-dependent (NHD) patients in terms of clinical outcomes., Methods: Between January 2000 and December 2013, there were 333 consecutive arteriosclerosis obliterans patients with CLI who underwent 401 PIMB procedures for limb salvage (LS). Of the 333 patients, 188 (56.5%) were HD patients. Vein grafts were exclusively used, and 172 paramalleolar and 229 inframalleolar bypasses were performed. Five-year primary and secondary cumulative graft patency, LS, and amputation-free survival (AFS) rates were compared between the two groups, and the independent determinants of these outcomes were identified in each group., Results: The 5-year primary and secondary cumulative graft patency rates were 53% and 82% in HD patients and 69% and 92% in NHD patients (primary cumulative graft patency, P < .05; secondary cumulative graft patency, nonsignificant), respectively. The LS rates were 87% and 99% (P < .01) in HD patients and NHD patients, respectively. Overall, 48% and 70% of HD and NHD patients were ambulatory before PIMB (P < .01), and 73% and 85% of HD and NHD patients were ambulatory 12 months after PIMB (including 1-year survivors; nonsignificant), respectively, demonstrating drastic post-PIMB improvement in HD patients. The 5-year AFS rates in the HD and NHD groups were 27% and 69% (P < .01), respectively, demonstrating very poor AFS rates in HD patients. In HD patients, factors negatively associated with AFS were female gender (hazard ratio [HR], 2.102; 95% confidence interval [CI], 1.254-3.524), history of congestive heart failure (HR, 2.075; 95% CI, 1.395-3.085), and preoperative nonambulatory status (HR, 1.974; 95% CI, 1.305-2.986), whereas older age (HR, 2.601; 95% CI, 1.372-4.931) and history of congestive heart failure (HR, 2.928; 95% CI, 1.496-5.731) were identified as independent factors negatively associated with AFS in NHD patients., Conclusions: The use of PIMB for CLI was associated with excellent LS rates in both HD and NHD patients with low operative mortality and complications. However, the AFS rate observed in HD patients was significantly lower than that observed in NHD patients, indicating the necessity of a specific management program to improve AFS after LS in HD patients., (Copyright © 2017 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
5. Cyclic adenosine monophosphate response-element binding protein activation by mitogen-activated protein kinase-activated protein kinase 3 and four-and-a-half LIM domains 5 plays a key role for vein graft intimal hyperplasia.
- Author
-
Nakanishi K, Saito Y, Azuma N, and Sasajima T
- Subjects
- Aged, Animals, Cell Movement, Cell Proliferation, Cells, Cultured, Constriction, Pathologic, Cyclic AMP Response Element-Binding Protein genetics, Disease Models, Animal, Gene Expression Profiling methods, Genetic Therapy, Graft Occlusion, Vascular etiology, Graft Occlusion, Vascular genetics, Graft Occlusion, Vascular pathology, Graft Occlusion, Vascular prevention & control, Humans, Hyperplasia, Intracellular Signaling Peptides and Proteins genetics, LIM Domain Proteins genetics, Male, Mice, Mice, Inbred C57BL, Muscle, Smooth, Vascular enzymology, Muscle, Smooth, Vascular pathology, Mutation, Myocytes, Smooth Muscle enzymology, Myocytes, Smooth Muscle pathology, Neointima, Oligonucleotide Array Sequence Analysis, Phosphorylation, Protein Binding, Protein Serine-Threonine Kinases genetics, Time Factors, Transcription Factors genetics, Transfection, Vascular System Injuries enzymology, Vascular System Injuries genetics, Vascular System Injuries pathology, Vascular System Injuries prevention & control, Veins enzymology, Veins injuries, Veins pathology, Cyclic AMP Response Element-Binding Protein metabolism, Graft Occlusion, Vascular enzymology, Intracellular Signaling Peptides and Proteins metabolism, LIM Domain Proteins metabolism, Protein Serine-Threonine Kinases metabolism, Transcription Factors metabolism, Vascular Grafting adverse effects, Veins transplantation
- Abstract
Objective: Intimal hyperplasia (IH) is the main cause of vein graft stenosis or failure after bypass surgery. Basic investigations are proceeding in an animal model of mechanically desquamated arteries, and numerous molecules for potential IH treatments have been identified; however, neither insights into the mechanism of IH nor substantially effective treatments for its suppression have been developed. The goals of the present study are to use human vein graft samples to identify therapeutic target genes that control IH and to investigate the therapeutic efficacy of these candidate molecules in animal models., Methods: Using microarray analysis of human vein graft samples, we identified two previously unrecognized IH-related genes, mitogen-activated protein kinase-activated protein kinase 3 (MAPKAPK3) and four-and-a-half LIM domains 5 (FHL5)., Results: Transfer of either candidate gene resulted in significantly elevated vascular smooth muscle cell (VSMC) proliferation and migration. Interestingly, cotransfection of both genes increased VSMC proliferation in an additive manner. These genes activated cyclic adenosine monophosphate response-element (CRE) binding protein (CREB), but their mechanisms of activation were different. MAPKAPK3 phosphorylated CREB, but FHL5 bound directly to CREB. A CREB dominant-negative protein, KCREB, which blocks its ability to bind CRE, repressed VSMC proliferation and migration. In a wire-injury mouse model, gene transfer of KCREB plasmid significantly repressed IH. In this vessel tissue, CRE-activated gene expression was repressed. Furthermore, we confirmed the changes in MAPKAPK3 and FHL5 expression using vein graft samples from eight patients., Conclusions: We successively identified two previously unrecognized IH activators, MAPKAPK3 and FHL5, using human vein graft samples. Gene transfer of KCREB repressed IH in an animal model. Inhibition of CREB function is a promising gene therapy strategy for IH., (Copyright © 2013 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
6. Hepatic artery aneurysm involving the proper hepatic and gastroduodenal artery treated using a gastroepiploic artery in situ bypass.
- Author
-
Kadohama T, Ohtani N, and Sasajima T
- Subjects
- Aneurysm diagnostic imaging, Humans, Male, Mesenteric Artery, Superior diagnostic imaging, Middle Aged, Radiography, Vascular Patency, Vascular Surgical Procedures, Aneurysm surgery, Gastroepiploic Artery transplantation, Hepatic Artery diagnostic imaging
- Abstract
We herein present the first known case of common hepatic artery aneurysm involving the proper hepatic artery treated with in situ bypass by using right gastroepiploic artery. A 55-year-old man was hospitalized after the incidental discovery of a low-echogenic mass with blood flow in the hepatic artery. Selective visceral arteriography demonstrated a hepatic artery aneurysm that filled via the superior mesenteric artery. The most proximal part of the common hepatic artery was occluded. A resection of aneurysm was performed, and the arterial blood flow was restored to the liver by mobilizing the right gastroepiploic artery and anastomosing the proper hepatic artery. This technique is preferable to grafting in that only one anastomosis is necessary and predicts that the results may be at least as good as with vein or prosthetic grafts.
- Published
- 2007
- Full Text
- View/download PDF
7. Homocysteine promotes p38-dependent chemotaxis in bovine aortic smooth muscle cells.
- Author
-
Akasaka K, Akasaka N, Di Luozzo G, Sasajima T, and Sumpio BE
- Subjects
- Animals, Blotting, Western, Cattle, Enzyme Inhibitors pharmacology, Imidazoles pharmacology, Phosphorylation, Pyridines pharmacology, Chemotaxis drug effects, Homocysteine pharmacology, Muscle, Smooth, Vascular cytology, p38 Mitogen-Activated Protein Kinases physiology
- Abstract
Objective: Increased levels of homocysteine in the blood are a risk factor for atherosclerosis. The purpose of this study was to examine the effects of homocysteine on smooth muscle cell (SMC) migration and to determine whether p38 was involved in this process., Methods: The effect of 0.5 to 2.0 mmol/L d , l -homocysteine as a chemoattractant for SMCs was assayed with a modified Boyden chamber. To determine the functional role of p38 in SMC chemotaxis induced by d , l -homocysteine, we treated SMCs with a p38 inhibitor, SB203580, before the assay., Results: The number of migrated cells was increased 7.0 +/- 1.2-fold (n = 15; P < .001) by 2.0 mmol/L d , l -homocysteine. SB203580 partially prevented the migration of SMCs toward homocysteine. Preconditioning SMCs with 2.0 mmol/L d , l -homocysteine significantly enhanced chemotaxis toward 10% fetal bovine serum compared with nonconditioned control SMCs (28.9 +/- 3.3-fold vs 15.6 +/- 2.8-fold; P < .05). There was a fourfold p38 activation after exposure of SMCs to 2.0 mmol/L d , l -homocysteine by immunoblot., Conclusions: These results suggest that homocysteine not only is a chemoattractant for SMC but can also enhance SMC chemotactic potential. The mechanism of these effects may involve p38 activation., Clinical Relevance: This study demonstrates that homocysteine can promote chemotaxis of SMCs through a p38-dependent pathway. To our knowledge, this is the first report that homocysteine may influence SMC chemotaxis. It may be an important mechanism for homocysteine-induced atherogenesis, because the migration of SMCs from the media is believed to play a critical role in progressive intimal thickening. Although homocysteine promotes atherogenesis and thrombosis by a variety of mechanisms, the effects of homocysteine on SMC proliferation and migration might be critical elements that may have potential therapeutic implications, because selective blockade of the p38 pathway is feasible.
- Published
- 2005
- Full Text
- View/download PDF
8. Biologic degeneration of vein grafts after thrombotic occlusion: thrombectomy within 3 days results in better indices of viability.
- Author
-
Kawai S, Sasajima T, Satoh K, Inaba M, Azuma N, Yamazaki K, and Oikawa K
- Subjects
- Animals, Cell Survival physiology, Dogs, Endothelium, Vascular metabolism, Endothelium, Vascular pathology, Endothelium, Vascular physiopathology, Epoprostenol biosynthesis, Female, Femoral Artery surgery, Graft Occlusion, Vascular etiology, Male, Thrombectomy, Time Factors, Veins surgery, Venous Thrombosis etiology, Venous Thrombosis metabolism, Blood Vessel Prosthesis adverse effects, Graft Occlusion, Vascular physiopathology, Vascular Patency physiology, Veins pathology, Venous Thrombosis pathology, Venous Thrombosis surgery
- Abstract
Objectives: To clarify the mechanism for poor patency of vein grafts after thrombectomy and the time limit for successful salvage operation, we investigated the time course of biologic degenerative changes in thrombosed vein grafts. Materials and methods The right femoral artery was replaced with a femoral vein graft in 25 mongrel dogs. After 3 months, grafts were explanted in 5 dogs (control grafts), and the remaining 20 dogs underwent femoral artery ligation to create a thrombosed graft. Of the 20 grafts, 5 were explanted at 3 days after ligation (group I-3) and 5 were explanted at 5 days after ligation (group I-5). Of the remaining 10 grafts, 5 underwent thrombectomy at 3 days after ligation (group II-3) and 5 underwent thrombectomy at 5 days after ligation, and were reimplanted into the left femoral artery, then explanted 28 days after reimplantation. The grafts were assessed with immunohistochemistry and prostaglandin (PG) I(2) assay (6-keto-PGI(1alpha))., Results: Of the 25 grafts, occlusion recurred in 3 in group II-5 within 28 days after reimplantation. There were significant differences between group I-5 and group I-3 or control grafts for percentage of areas positive for alpha-actin, total number of cells per field, and proliferating cell nuclear antigen (PCNA)-positive cells in layer of thickened intima and atrophied media (I/M), and for total cell and PCNA- positive cell numbers per field in the adventitia. Mean 6-ketoPGF(1alpha) was 40 +/- 14.1 pg/mg/min in control dogs, 84 +/- 18.9 pg/mg/min in group I-3, and 15.4 +/- 7.7 pg/mg/min in group I-5, demonstrating a significant reduction in group I-5 (P =.009)., Conclusion: Graft wall cell viability and PGI(2) production in thrombosed vein grafts are well preserved for up to 3 days. Therefore graft salvage operations no later than 3 days after thrombotic occlusion may provide acceptable long-term patency of salvaged grafts.
- Published
- 2003
- Full Text
- View/download PDF
9. Novel anastomotic method enables aortofemoral bypass for patients with porcelain aorta.
- Author
-
Sasajima T, Inaba M, Azuma N, Akasaka N, Asada H, Uchida H, Sasajima Y, and Goh K
- Subjects
- Aged, Aorta physiopathology, Aortic Diseases diagnostic imaging, Aortic Diseases physiopathology, Aortography, Female, Femoral Artery diagnostic imaging, Femoral Artery physiopathology, Humans, Male, Middle Aged, Retrospective Studies, Treatment Outcome, Anastomosis, Surgical methods, Aorta surgery, Aortic Diseases surgery, Femoral Artery surgery
- Abstract
Purpose: Porcelain aorta is an indication for axillofemoral bypass. However, the procedure has definitive flaws. We present a new method for achievement of aortofemoral bypass., Methods: The portion of the distal aorta for anastomosis is wrapped with a double polytetrafluoroethylene mesh and fixed to the adventitia with continuous sutures. The adventitia of the anastomotic site is cut over the mesh until the calcified surface is disclosed. Margins of the mesh and the peeled adventitia are fixed along the anastomotic margin with continuous sutures. After the aorta and distal arteries are occluded with balloon catheters, an opening on the bared calcification is made with an airdrill and enlarged with a laminectomy rongeur. The anastomosis is performed between a graft and the mesh-reinforced adventitia with continuous sutures. Over 6 years, this method has been applied to nine patients with porcelain aorta who are diabetic or undergoing dialysis. The indications were disabling claudication in three patients and limb salvage in six patients., Results: No anastomotic complications or operative deaths were seen, and satisfactory mid-term results were obtained, with follow-up ranging from 3 to 62 months after surgery. One patient died of coronary heart disease 3 years after surgery, but the grafts retained a good function., Conclusion: This method is safe and effective, and more liberal application of this method may help improve outcome and quality of life.
- Published
- 2002
- Full Text
- View/download PDF
10. Limitations in the use of rifampicin-gelatin grafts against virulent organisms.
- Author
-
Koshiko S, Sasajima T, Muraki S, Azuma N, Yamazaki K, Chiba K, Tachibana M, and Inaba M
- Subjects
- Animals, Antibiotics, Antitubercular administration & dosage, Blood Vessel Prosthesis Implantation, Dogs, Escherichia coli drug effects, Gelatin, Methicillin Resistance, Microbial Sensitivity Tests, Rifampin administration & dosage, Staphylococcus aureus drug effects, Staphylococcus epidermidis drug effects, Time Factors, Antibiotics, Antitubercular pharmacology, Blood Vessel Prosthesis adverse effects, Escherichia coli Infections prevention & control, Prosthesis-Related Infections drug therapy, Rifampin pharmacology, Staphylococcal Infections prevention & control
- Abstract
Objective: Efficacy and duration of antibacterial activity of rifampicin-gelatin grafts against virulent organisms were evaluated in an animal model., Materials and Methods: Rifampicin-gelatin grafts were prepared with impregnation of Gelseal (Vascutek Ltd, Scotland) graft in 1 mg/mL rifampicin solution. Rifampicin-gelatin grafts (6 cm long; n = 24) and plain Gelseal grafts as controls (n = 4) were implanted into the canine abdominal aorta with inoculation of Staphylococcus epidermidis, Escherichia coli, or methicillin-resistant Staphylococcus aureus (MRSA), and the rifampicin-gelatin grafts were retrieved after 1 to 4 weeks. Disks cut from the retrieved rifampicin-gelatin grafts were placed on agar plates streaked with one of the organisms, and the graft antibacterial activity was assessed with the width of the inhibition zone., Results: In in vitro tests, initial inhibition zones (inhibition zone of 24 hours after incubation) of rifampicin-gelatin grafts against S epidermidis, MRSA, and E coli were 40.0 +/- 0.3 mm, 36.0 +/- 0.2 mm, and 11.8 +/- 0.1 mm, respectively. In the implantation, S epidermidis -inoculated rifampicin-gelatin grafts had no findings of graft infection, and no colony growth was recognized on the plates streaked with the perigraft fluids. Initial inhibition zones of S epidermidis -inoculated rifampicin-gelatin grafts retrieved at 1 or 2 weeks were 20.1 +/- 1.1 mm and 7.6 +/- 1.0 mm, respectively. In E coli -inoculated and MRSA-inoculated rifampicin-gelatin grafts, all of the eight animals had perigraft abscess, and blood culture test results probed septicemia in five animals with patent grafts at death. Inhibition zones against E coli or MRSA were not formed on the plates streaked with the same organism, whereas initial inhibition zones of E coli -inoculated and MRSA-inoculated rifampicin-gelatin grafts on S epidermidis -streaked plates were 8.0 +/- 0.2 mm and 18.5 +/- 0.5 mm, respectively. In the MRSA group, however, recolonization of high minimal inhibitory concentration strains developed within the inhibition zones as early as 24 hours. Histologically, neither organisms nor inflammatory cells were found in S epidermidis -inoculated rifampicin-gelatin grafts and tissue ingrowth was recognized at 2 to 4 weeks, whereas E coli -inoculated and MRSA-inoculated rifampicin-gelatin grafts had aggressive neutrophil infiltration into the graft interstices, revealing establishment of uncontrollable graft infection., Conclusion: These results suggested that rifampicin-gelatin grafts are clearly valid for S epidermidis infection, whereas no efficacy was recognized against either MRSA or E coli graft infection because of early development of high minimal inhibitory concentration MRSA strains or poor susceptibility.
- Published
- 2002
- Full Text
- View/download PDF
11. Endothelial cell response to different mechanical forces.
- Author
-
Azuma N, Duzgun SA, Ikeda M, Kito H, Akasaka N, Sasajima T, and Sumpio BE
- Subjects
- Animals, Aorta cytology, Cattle, Cells, Cultured, Enzyme Activation, Focal Adhesion Kinase 1, Focal Adhesion Protein-Tyrosine Kinases, Focal Adhesions physiology, Humans, Immunoblotting, JNK Mitogen-Activated Protein Kinases, Mechanoreceptors physiology, Phosphorylation, Protein-Tyrosine Kinases physiology, Stress, Mechanical, Endothelium, Vascular physiology, Mitogen-Activated Protein Kinases physiology, Signal Transduction physiology
- Abstract
Purpose: Endothelial cells (ECs) are subjected to the physical forces induced by blood flow. The aim of this study was to directly compare the EC signaling pathway in response to cyclic strain and shear stress in cultured bovine aortic ECs., Materials and Methods: The ECs were seeded on flexible collagen I-coated silicone membranes to examine the effect of cyclic strain. The membranes were deformed with a 150-mm Hg vacuum at a rate of 60 cycle/min for up to 120 minutes. For a comparison of the effect of shear stress, ECs from the same batch as used in the strain experiments were seeded on collagen I-coated silicone sheets. The ECs were then subjected to 10 dyne/cm(2) shear with the use of a parallel flow chamber for up to 120 minutes. Activation of the mitogen- activated protein kinases was assessed by determining phosphorylation of extracellular signal-regulated kinase (ERK), c-jun N-terminal kinase (JNK), and p38 with immunoblotting., Results: ERK, JNK, and p38 were activated by both cyclic strain and shear stress. Both cyclic strain and shear stress activated JNK with a similar temporal pattern and magnitude and a peak at 30 minutes. However, shear stress induced a more robust and rapid activation of ERK and p38, compared with cyclic strain., Conclusions: Our results indicate that different mechanical forces induced differential activation of mitogen-activated protein kinases. This suggests that there may be different mechanoreceptors in ECs to detect the different forces or alternative coupling pathways from a single receptor.
- Published
- 2000
- Full Text
- View/download PDF
12. Immunosuppression with FK506 in rat arterial allografts: fate of allogeneic endothelial cells.
- Author
-
Azuma N, Sasajima T, and Kubo Y
- Subjects
- Animals, Immunohistochemistry, Male, Rats, Rats, Inbred ACI, Rats, Inbred Lew, Regeneration physiology, Tacrolimus administration & dosage, Transplantation, Homologous, Arteries transplantation, Endothelium, Vascular cytology, Immunosuppression Therapy, Tacrolimus pharmacology
- Abstract
Purpose: This study clarified the efficacy of low-dose FK506 and the possibility of discontinuing the use of FK506., Methods: Fresh carotid arteries were allografted from ACI rats to Lewis rats. FK506 (0.2 mg/kg/day) was given intramuscularly from day 3 after transplantation until the rats were killed (group III), or it was given for 4 weeks and then discontinued (group IV). Isogeneic (group I) and allogeneic (group II) models served as untreated control groups. Grafts were harvested on days 0, 1, 3, 7, 14, 21, 28, 70, and 105 after transplantation. Histological evaluation and measurement of the endothelial cell (EC)-covered area were performed by means of scanning electron microscopy., Results: In group I, ECs were denuded immediately after transplantation and subsequently regenerated within 2 weeks. In group II, after denudation and regeneration of ECs, massive leukocyte adhesion and subsequent destruction of regenerated ECs, followed by intimal hyperplasia, were observed. In group III, FK506 suppressed rejection almost completely, without intimal hyperplasia. In group IV, severe rejection and denudation of regenerated intima appeared 2 weeks after the use of FK506 ended., Conclusion: The denudation and regeneration of ECs may play an important role in the process of rejection and graft performance. FK506 proved to be successful in rat arterial allografting, and ECs of donor origin could survive on the allograft as long as FK506 was effective; however, cessation of the use of FK506 resulted in severe destruction of intima. To prevent allograft failure, long-term administration of an immunosuppressant is essential.
- Published
- 1999
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.